Litfulo 50 mg/1

Ritlecitinib, the active ingredient in Litfulo, is a Janus kinase (JAK) inhibitor presented as a 50 mg capsule for oral use. It is used to treat severe alopecia areata in adults and adolescents 12 years and older to reduce hair loss and promote regrowth. GNH USA supplies Litfulo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Litfulo is designed to target and selectively block specific inflammatory proteins involved in hair loss, such as Janus kinase 3 (JAK3) and TEC kinases. This action helps reduce the number of inflammatory cells attacking the hair follicle, allowing for hair regrowth. The medication is available as a 50 mg capsule and is taken once daily.

Litfulo is primarily used to treat severe alopecia areata, a condition that causes significant hair loss. It works by targeting specific inflammatory proteins involved in the immune response that attacks hair follicles.

- Alopecia areata: Reduces hair loss and promotes hair regrowth in adults and adolescents 12 years and older. - Severe alopecia areata: Helps achieve significant scalp hair coverage, including eyelash and eyebrow regrowth. - Immune-mediated hair loss: Targets the underlying inflammatory processes that contribute to hair loss.

Litfulo can cause various side effects, ranging from common to serious. Common side effects include mild to moderate symptoms, while serious or rare side effects are less frequent but more severe.

Common Side Effects: - Headache: A frequent side effect reported by users. - Diarrhea: May occur during treatment. - Acne: Skin-related side effects are possible. - Rash: Including urticaria and atopic dermatitis. - Fever: Mild to moderate fever may be experienced. - Dizziness: Some users may feel lightheaded.

Serious or Rare Side Effects: - Serious infections: Increased risk of infections due to immune system suppression. - Blood clots: Higher rate of blood clot formation. - Cancer: Increased risk of developing certain types of cancer. - Heart attack and stroke: Higher rate of cardiovascular events. - Mouth ulcers: Severe mouth sores may occur.

Litfulo should be used with caution and under the supervision of a healthcare provider. Important precautions include monitoring for infections, cardiovascular events, and other serious side effects.

- Infections: Monitor for signs of infection and seek medical attention if symptoms occur. - Cardiovascular events: Regularly check for signs of heart attack or stroke. - Cancer: Be aware of the increased risk of cancer and report any unusual symptoms. - Blood clots: Take precautions to prevent blood clots, such as staying active and hydrated. - Pregnancy: The safety of Litfulo during pregnancy is unknown; consult a healthcare provider. - Breastfeeding: The safety of Litfulo during breastfeeding is unknown; consult a healthcare provider. - Store at 20°C to 25°C: Keep in the original package, protect from moisture, and keep out of reach of children.

Litfulo can interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. Major interactions should be avoided, while moderate interactions require close monitoring.

Major Interactions (Avoid): - Immunosuppressants: Avoid concurrent use with other immunosuppressants to prevent excessive immune suppression. - Anticoagulants: Avoid concurrent use to prevent an increased risk of bleeding. - Biologics: Avoid concurrent use to prevent excessive immune suppression.

Moderate Interactions (Monitor Closely): - NSAIDs: Monitor for increased risk of gastrointestinal side effects. - Corticosteroids: Monitor for increased risk of infections and other side effects. - Antidiabetics: Monitor blood sugar levels closely.